Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Recruiting now

Conditions studied: Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL

In brief

This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.

Key facts

Study ID

NCT04014374

Run by

Kyowa Kirin, Inc.

People needed

150

Starts

2019-09-10

Expected to finish

2030-02-01

Last updated by the study team

2024-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
• Adults ≥18 years of age with either CTCL or ATLL;
• AlloHCT performed from January 2012 onward.

You may not qualify if…

• Patients without consent for research.

Where it is running

• CIBMTR — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.